Publication of Form 20-F

RNS Number : 2361R

Hutchison China Meditech Limited

04 March 2021

 

Press Release

Publication of Form 20-F

Hong Kong, Shanghai & Florham Park, NJ: Thursday, March 4, 2021: Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) today published the Form 20-F for the financial year ended December 31, 2020.  This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/2361R_1-2021-3-4.pdf and also on the website of the Company at www.hutch-med.com.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has advanced ten cancer drug candidates from discovery into clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.hutch-med.com.

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President	[phone]
Annie Cheng, Vice President	[phone]
Media Enquiries
Americas - Brad Miles, Solebury Trout	[phone]   (Mobile)  [e-mail]
Europe - Ben Atwell / Alex Shaw, FTI Consulting	[phone] / [phone]   (Mobile) / [phone] (Mobile) [e-mail]
Asia - Joseph Chi Lo / Zhou Yi, Brunswick	[phone] (Mobile), [e-mail] / [phone]   (Mobile), y [e-mail]
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited	[phone]

 

END

 

 

ACSFLFIEVEISIIL